Literature DB >> 1233212

Distribution and elimination kinetics of carbamazepine in man.

M D Rawlins, P Collste, L Bertilsson, L Palmér.   

Abstract

Carbamazepine (2.7-3 mg/kg) was administered orally as an alcoholic solution (50% v/v) to eight healthy volunteers. Two of the subjects were also given 50 mg and 100 mg of carbamazepine in alcoholic solution and 200 mg as a tablet. Plasma concentrations, which were analysed by mass fragmentography, reached a maximum 1-7 hours after dosing, and then declined monoexponentially with half-lives ranging from 24 to 46 hours. The half-lives were independent of dose. The apparent distribution volume ranged from 0.79 to 1.40 1/kg. It was found that 72% of carbamazepine was bound to plasma proteins with little interindividual variation, and this was not influenced by the presence of diphenylhydantoin or phenobarbital in therapeutic concentrations. The pharmacokinetic parameters calculated from single oral doses were used to predict the steady-state plasma concentration expected after treatment with multiple doses of 200 mg three times daily. The predicted steady-state concentration was 2-3 times higher than that reported in patients undergoing chronic treatment with carbamazepine at this dose level, i.e. the pharmacokinetics of carbamazepine apparently change during multiple dosing.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233212     DOI: 10.1007/bf00561556

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Quantitative determination of carbamazepine in plasma by mass fragmentography.

Authors:  L Palmér; L Bertilsson; P Collste; M Rawlins
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

2.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

3.  The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.

Authors:  G H Evans; A S Nies; D G Shand
Journal:  J Pharmacol Exp Ther       Date:  1973-07       Impact factor: 4.030

4.  Preliminary observations of serum carbamazepine concentration in epileptic patients.

Authors:  J J Cereghino; J C Meter; J T Brock; J K Penry; L D Smith; B G White
Journal:  Neurology       Date:  1973-04       Impact factor: 9.910

5.  Pharmacokinetics of lidocaine in man.

Authors:  R N Boyes; D B Scott; P J Jebson; M J Godman; D G Julian
Journal:  Clin Pharmacol Ther       Date:  1971 Jan-Feb       Impact factor: 6.875

6.  The binding of chlorothiazide to plasma proteins.

Authors:  A Breckenridge; A Rosen
Journal:  Biochim Biophys Acta       Date:  1971-03-23

7.  Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man.

Authors:  J M Hansen; K Siersboek-Nielsen; L Skovsted
Journal:  Clin Pharmacol Ther       Date:  1971 May-Jun       Impact factor: 6.875

8.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

9.  Use of carbamazepine in epilepsy. Results in 87 patients.

Authors:  S Livingston; C Villamater; Y Sakata; L L Pauli
Journal:  JAMA       Date:  1967-04-17       Impact factor: 56.272

10.  Facial pain treated with carbamazepin (Tegretol).

Authors:  P Rasmussen; J Riishede
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

View more
  28 in total

1.  Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses.

Authors:  A P Géradin; F V Abadie; J A Campestrini; W Theobald
Journal:  J Pharmacokinet Biopharm       Date:  1976-12

2.  Use of saliva in monitoring carbamazepine medication in epileptic children.

Authors:  H Bartels; H D Oldigs; E Günther
Journal:  Eur J Pediatr       Date:  1977-08-23       Impact factor: 3.183

3.  Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.

Authors:  C J van Boxtel; J T Wilson; S Lindgren; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

4.  Enhanced clearance of carbamazepine using albumin-containing dialysate during CVVHDF.

Authors:  Joon Seok Choi; Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Seung Jung Kee; Young Jong Woo; Soo Wan Kim
Journal:  Intensive Care Med       Date:  2012-10-25       Impact factor: 17.440

Review 5.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

6.  Time course of carbamazepine self-induction.

Authors:  P J McNamara; W A Colburn; M Gibaldi
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

7.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Authors:  Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

8.  Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients.

Authors:  J J MacKichan; P K Duffner; M E Cohen
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

Review 9.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of carbamazepine.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.